Achondroplasia
Achondroplasia is a genetic disorder that results in abnormal bone growth, leading to short stature and characteristic features such as a larger head and shorter limbs. It is the most common form of dwarfism.
Achondroplasia: Long-Term Study of Infigratinib
We are studying the long-term safety and effects of Infigratinib in children with Achondroplasia. The goal is to see how it impacts their growth and overall health.
>2 yearsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesOralOrthopedics and TraumatologyPediatrics
What diseases are being studied?
Health conditions and diseases that the clinical trial is designed to study and treat.
Who can participate in the clinical trial?
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
- Are you between 3 and 17 years old?
- Do you have achondroplasia (ACH) confirmed by genetic testing?
- Are you currently pregnant or have you had a positive pregnancy test if you are a girl aged 10 or older?
- Have you had a fracture in the past 12 months?
- Are you currently taking any medications that affect the liver, like certain antibiotics or antifungals?
What experimental substances are being tested?
Experimental substances that are being investigated in this clinical trial. These are not yet approved for general use.
Infigratinib
Where is the clinical trial being conducted?
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Loading map...
Hopital Des Enfants
Pediatric Endocrinology Department
Blagnac, France
Hospital Femme Mere Enfant
Genetic Department
Bron, France
Hopital Necker Enfants Malades
Service de Médecine Génomique des Maladies Rares
Montrouge, France
Sponsor: Qed Therapeutics Inc.
Last updated: Nov 26, 2025
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.